Uterine Fibroids Segment May Offer Opportunity for NBIX
According to MarketScan and Truven Health Analytics, approximately 9 million women in the US need therapy for symptoms related to uterine fibroids (or UF).
While Neurocrine Biosciences (NBIX) invented and developed Elagolix until Phase 2 trials, it is currently being tested in Phase 3 trials by AbbVie (ABBV).
Neurocrine Biosciences (NBIX) is currently involved in two phase two trials, T-Forward and T-Force GREEN, which are exploring Valbenazine as a therapy for Tourette Syndrome (or TS).
If Valbenazine manages to secure FDA approval, it could have a positive impact on Neurocrine Biosciences stock.
In Neurocrine Biosciences’ (NBIX) phase three trial Kinect-3, investigational therapy Valbenazine has managed to demonstrate statistically significant improvement.
Wall Street analysts have projected that Neurocrine Biosciences’ net income in 2016 will be -$146.2 million, a significantly higher loss than in 2015.
Unlike Biogen (BIIB) and Eli Lilly, who have focused their attention on amyloid-beta based therapeutics, AbbVie (ABBV) is reluctant to enter this field.
In 2015, the US healthcare system spent ~$225 billion on patients suffering from Alzheimer’s. About 115 million people will suffer from the disease by 2050.
On November 22, 2016, Boston Scientific (BSX) announced the completion of its acquisition of EndoChoice Holdings. The deal was valued at $210 million in cash at a price of $8.00 per share.
On November 29, 2016, Nevro Corp. (NVRO) filed a lawsuit against Boston Scientific, claiming patent infringement on its patents for Senza and HF10 spinal cord stimulation therapies for chronic back pain.
Developed by Boston Scientific (BSX), HeartLogic is a system of sensors that can be attached to defibrillator devices. These sensors can monitor the patient and predict heart failure events.
Boston Scientific (BSX) stock has fallen ~7.4% since the release of the company’s 3Q16 earnings on October 26, 2016.
In a November 30 survey of 26 brokerage companies, ~81% of these analysts rated Boston Scientific (BSX) as a “buy” and 19% rated it as a “hold.” None of the analysts rated Boston Scientific as a “sell.”
With Merck’s revenue growth with drugs like Keytruda and Gardasil, analysts estimate that it will generate EPS of $0.92 and sales of $10.2 billion in 4Q16.
Merck’s profitability improved via a 5% rise in revenue in 3Q16. Its adjusted net income rose to ~$2.3 billion in 3Q16, compared to ~$1.8 billion in 3Q15.
Remicade is one of Merck’s (MRK) blockbuster drug and is a top-selling drug for the treatment of inflammatory disorders.
Merck’s (MRK) Animal Health segment operates in more than 140 countries worldwide. The global sales reported for 3Q16 totaled ~$865 million.
Total sales from Merck’s Gardasil during 3Q16 reached $860 million, a rise of ~38% over the $625 million in 3Q15.
Januvia and Janumet are two blockbuster drugs in Merck’s diabetes franchise. These drugs help lower blood sugar level in patients with type-2 diabetes.
Keytruda was launched by Merck in the fourth quarter of 2014 and reported global sales of $356 million in 3Q16, resulting in more than 100% growth.